Pharmacyclics, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pharmacyclics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Pharmacyclics, Inc. - Product Pipeline Review - 2015', provides an overview of the Pharmacyclics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmacyclics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharmacyclics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharmacyclics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pharmacyclics, Inc.'s pipeline products

Reason to Buy

- Evaluate Pharmacyclics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharmacyclics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharmacyclics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharmacyclics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmacyclics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Pharmacyclics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Pharmacyclics, Inc. Snapshot 5
Pharmacyclics, Inc. Overview 5
Key Information 5
Key Facts 5
Pharmacyclics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pharmacyclics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pharmacyclics, Inc. - Pipeline Products Glance 12
Pharmacyclics, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Pharmacyclics, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Pharmacyclics, Inc. - Drug Profiles 15
ibrutinib 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PCI-27483 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
abexinostat hydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Inhibit BTK for Autoimmune Disorders and Rheumatoid Arthritis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Pharmacyclics, Inc. - Pipeline Analysis 26
Pharmacyclics, Inc. - Pipeline Products by Target 26
Pharmacyclics, Inc. - Pipeline Products by Route of Administration 27
Pharmacyclics, Inc. - Pipeline Products by Molecule Type 28
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action 29
Pharmacyclics, Inc. - Recent Pipeline Updates 30
Pharmacyclics, Inc. - Dormant Projects 46
Pharmacyclics, Inc. - Discontinued Pipeline Products 47
Discontinued Pipeline Product Profiles 47
PCI-45292 47
Pharmacyclics, Inc. - Company Statement 48
Pharmacyclics, Inc. - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Pharmacyclics, Inc., Key Information 5
Pharmacyclics, Inc., Key Facts 5
Pharmacyclics, Inc. - Pipeline by Indication, 2015 7
Pharmacyclics, Inc. - Pipeline by Stage of Development, 2015 8
Pharmacyclics, Inc. - Monotherapy Products in Pipeline, 2015 9
Pharmacyclics, Inc. - Partnered Products in Pipeline, 2015 10
Pharmacyclics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Pharmacyclics, Inc. - Phase III, 2015 12
Pharmacyclics, Inc. - Phase II, 2015 13
Pharmacyclics, Inc. - Phase I, 2015 14
Pharmacyclics, Inc. - Pipeline by Target, 2015 26
Pharmacyclics, Inc. - Pipeline by Route of Administration, 2015 27
Pharmacyclics, Inc. - Pipeline by Molecule Type, 2015 28
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action, 2015 29
Pharmacyclics, Inc. - Recent Pipeline Updates, 2015 30
Pharmacyclics, Inc. - Dormant Developmental Projects,2015 46
Pharmacyclics, Inc. - Discontinued Pipeline Products, 2015 47
Pharmacyclics, Inc., Subsidiaries 50